Norihiko Matsuo

What’s the largest city in China? It’s Chongqing, with a population of 33 million. Parexel RWE and Scientific Data Organization is visiting Chongqin today, f2f meeting local RWD network of more than 100 hospitals. This visit is partially sponsored by the Parexel Innovation Engine, and the Parexel Greater China Region. The problem? The air temperature in Chongqin is 40c(104F) today. Hopefully we can survive double hits, I.e., extreme heat and extremely messy data.

49

1件のコメント

“Friends of RWE” is approaching 50th episode! This is a bi-weekly seminar series I started in Parexel APAC since 2020 (I left for two years and rejoined in 2023). The audience is Parexel APAC leaders, who are interested in RWD/E. The original goal was to increase the awareness of RWD/E among them, so my everyday work would get easier (selfish, right?) Over the years, on this stage, together we have witnessed the first ECA in China; the rise and fall of China’s League of Data Heroes; celebrated DS8201’s success; studied Novartis’ Data42; analyzed RWD utility in COVID studies; reviewed why/how some RWE studies failed; dropped our jaws on the US-China data wars… Only four people came to the 1st seminar; last week, more than 80 “Friends of RWE”came and learned the regulations on “cross-border data flow”, an increase of 20X in four years. So, with so many “Friends of RWE”, is my everyday life in RWE getting easier? A piece of cake? Not really.

14

I visited RWE clients, partners, data owners, KOLs in China during the past three weeks. What did I learn? 1. Overall, local RWD/RWE opportunities are growing sharply in 2024, compared to 2023; 2. Overall, RWD availability, accessibility and data technology are improving fast, while data quality, clinical readiness and the transparency of operational procedures remain hurdles. However, for some studies, this is not a killing factor; 3. When I introduced Disease Registries, and criticized that local KOL’s impact was way too strong, I got even stronger feedback from a KOL:”if you want to operate in China, you need to understand local.” What she did not know was, I already lowered my tone. I did not disagree with her, although I did not like it. Unlike RCTs, in RWE, local powerhouses still dominate, before market grows more maturely in China, whether you like it or not. The picture was taken last night in Chingqin, from a bridge over the Yangzi River, beautiful and mysterious.

26

6件のコメント

APAC is playing an increasingly important role in development and manufacturing of biologics. I am looking forward to sharing some practical insights into developing and manufacturing targeted therapeutics at the BCMA conference Singapore this September. #CDMO #antibodies

22

1件のコメント

𝐒𝐨𝐮𝐭𝐡 𝐊𝐨𝐫𝐞𝐚𝐧 𝐛𝐢𝐨𝐭𝐞𝐜𝐡𝐬 𝐦𝐨𝐯𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐔𝐒... Radyus Research and Dt&CRO a South Korean preclinical contract research organization, have formed a partnership to facilitate South Korean biotech companies' entry into the U.S. market. The collaboration aims to assist in regulatory processes, IND applications, and first-in-human trials in the U.S. In return, Radyus gains access to Dt&CRO's lab testing services for its Asia-based clients. This agreement leverages the growing interest of South Korean biotech firms in the U.S. market, as evidenced by several companies establishing subsidiaries, headquarters, and research centres in America in recent years. #cro https://lnkd.in/enESQk2a

13

1件のコメント